DOCSLIB.ORG

WORLD MEDICAL INNOVATION FORUMSM CANCER | APRIL 25–27, 2016 World Medical Innovation Forum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WORLD MEDICAL INNOVATION FORUMSM CANCER | APRIL 25–27, 2016 World Medical Innovation Forum WORLD MEDICAL INNOVATION FORUMSM CANCER | APRIL 25–27, 2016 World Medical Innovation Forum PARTNERS HEALTHCARE Headquartered in Boston, The World Medical Innovation Forum is a global Massachusetts, Partners HealthCare gathering of more than 1,200 senior health care is one of the nation's most highly leaders hosted by Partners HealthCare in the regarded hospital systems. Its founding institutions, Brigham and heart of Boston. It was established to respond to Women’s Hospital and Massachusetts the intensifying transformation of health care and General Hospital, are staffed by its impact on innovation. The Forum is rooted in Harvard Medical School faculty the belief that no matter the magnitude of that and have a legacy of innovation change, the center of health care needs to be a that includes 18 Nobel Laureates and therapies that have redefined shared, fundamental commitment to collaborative the contemporary standard of care. innovation – industry and academia working It's the largest academic research together to improve patient lives. enterprise in the nation at more than $1.5 billion of annual research. The 2016 World Medical Innovation Forum will Its staff is responsible for hundreds feature the newest technologies to diagnose, treat of products and best practices and manage cancer. that benefit millions of patients worldwide. CANCER | April 25–27, 2016 CARDIOVASCULAR | May 1–3, 2017 Keynoters Joseph Jimenez Giovanni Caforio, MD CEO, Novartis CEO, Bristol-Myers Squibb Robert Bradway Richard Gonzalez CEO, Amgen CEO, AbbVie Robert Mulroy Michael Pellini, MD CEO, Merrimack Pharmaceuticals CEO, Foundation Medicine Briggs Morrison, MD David Schenkein, MD CEO, Syndax Pharmaceuticals CEO, Agios Pharmaceuticals David Lee Bruno Strigini CEO, Lumicell President, Novartis Oncology Marc de Garidel William Hait, MD, PhD CEO, Ipsen Global Head, Janssen R&D, J&J Paul Hudson Gary Reedy President, AstraZeneca US, CEO, American Cancer Society Executive Vice President, Thomas Lynch, MD AstraZeneca North America CEO, Mass General David Torchiana, MD Physician’s Organization CEO, Partners HealthCare Monica Bertagnolli, MD Daniel Haber MD, PhD Chief, Division of Surgical Oncology, Director, Massachusetts General Hospital Brigham and Women’s Hospital, Cancer Center, Kurt J. Isselbacher/Peter D. Professor of Surgery, Schwartz Professor of Oncology, Harvard Medical School Harvard Medical School Judy Salerno, MD Glenn Dranoff , MD CEO, Susan G. Komen for the Cure Global Head of Exploratory Immuno- William Sellers, MD Oncology, Novartis Institutes for Vice President and Global Head of Biomedical Research Oncology, Novartis Institutes for Christopher Viehbacher BioMedical Research Managing Partner, Gurnet Point Capital Nancy Snyderman, MD Henri Termeer Medical Advisor, Jean-François Formela, MD GE Healthymagination Partner, Atlas Venture Amir Nashat, PhD Bob Tepper, MD Managing Partner, Polaris Partners Partner, Third Rock Ventures Jim Robinson Kathy Giusti President, Astellas Pharma US Founder and Executive Chairman, MMRF Francis Cuss, MD Executive Vice President and Chief Scientifi c Offi cer, R&D, Bristol-Myers Squibb Every Speaker an Expert. Every Panel Unique. Every Seat Invaluable. Featured speakers include more than 100 CEOs, top cancer innovators, leading investors, and national journalists. Sponsors Panels PRESENTING MON. APRIL 25, 2016 8:00 AM - 8:00 PM TUES. APRIL 26, 2016 8:15 AM - 6:45 PM WED. APRIL 27, 2016 8:10 AM - 1:20 PM STAKEHOLDER A War or Moonshot: Where Do We Stand? Arms Race in Radiation Breakthrough Devices to Treat Cancer Building and Managing a Disruptive Cancer Pipeline Cancer Diagnostics: New Uses, New Reimbursements? Combination Cancer Therapies: Drug Resistance and Therapeutic Index Curative Therapies: Game Changing Science and its New Economics STRATEGIC Discovery Cafe: Top Faculty Share Their Work Disruptive Dozen Early Detection and Prevention of Cancer Epigenetics and Novel Cancer Targets First Look: The Next Wave of Cancer Breakthroughs Funding the Next Cancer Companies Global Economics of Cancer: Markets in Transition Immunotherapy I: Checkpoint Activation and Cancer Vaccines Immunotherapy II: Cell Based Therapies COLLABORATORS New Philanthropy: Patients Driving Innovation Study Designs to Meet the Challenges of Personalized Cancer Medicines Successful Portfolio Strategy Surviving Cancer: New Realities, New Needs Breakthrough Technologies FIRST LOOK The Next Wave of Cancer Breakthroughs Monday Morning | 8AM – 12PM DISCOVERY CAFÉ LUNCH Enjoy Lunch with Top Cancer Leadership Please join us as some of our most creative investigators from across Partners HealthCare describe their most promising commercially related research. Rapid-fire presentations by two dozen early-career Monday Lunch | 12PM – 1:30PM Harvard Medical School faculty will highlight compelling Top faculty from Brigham and Women's Hospital, new discoveries and insights that will be the cancer care Massachusetts General Hospital and Dana-Farber Cancer products of the future. If identifying new high impact cancer Institute will host intimate lunch discussions on developments technology is your passion—as an investor, company leader, in their field and their own research. Forum attendees are donor, entrepreneur or investigator—this session is for you. invited to engage with these internationally renowned leaders These young stars from Brigham and Women's Hospital, on topics ranging from the integration of specific oncology Massachusetts General Hospital and Dana-Farber Cancer therapies to the newest diagnostic methods. This will be an Institute will each describe their work in highly organized exciting and energized session with abundant opportunities 10-minute sessions. for direct exchanges with these world leaders. Open registration for tables by topic/speaker (8 guests per table) is Speakers available as part of World Forum registration. All speakers are affiliated with Harvard Medical School Cyril Benes, PhD, MGH Speakers Priscilla Brastianos, MD, MGH All speakers are affiliated with Harvard Medical School Mark Cobbold, MD, PhD, MGH Kenneth Anderson, MD, BWH Ryan Corcoran, MD, PhD, MGH Monica Bertagnolli, MD, BWH Jeannie Lee, MD, PhD, MGH Shawn Demehri, MD, PhD, MGH Joan Brugge, PhD, HMS Maximo Loda, MD, BWH Daniela Dinulescu, PhD, BWH George Demetri, MD, Jay Loeffler, MD, MGH Ritu Gill, MD, BWH Dana-Farber Robert Martuza, MD, MGH Wilhelm Haas, PhD, MGH Don Dizon, MD, MGH Marcela Maus, MD, PhD, Lida Hariri, MD, PhD, MGH David Fisher, MD, PhD, MGH MGH Aditi Hazra, PhD, BWH Keith Flaherty, MD, MGH Ann Partridge, MD, Jayender Jagadeesan, PhD, BWH Levi Garraway, MD, PhD, Dana-Farber Hakho Lee, PhD, MGH Dana-Farber Scott Rodig, MD, PhD, BWH Alexander Lin, PhD, BWH Jeffrey Golden MD, BWH Deborah Schrag, MD, BWH, Dana-Farber Sandra McAllister, PhD, BWH Daniel Haber, MD, PhD, MGH Arlene Sharpe, MD, PhD, Mikael Pittet, PhD, MGH Elizabeth Henske, MD, BWH, Dana-Farber BWH, Dana-Farber Miguel Rivera, MD, MGH Theodore Hong, MD, MGH Julie Silver, MD, Spaulding Sandro Santagata, MD, PhD, BWH John Iafrate, MD, MGH Kimberly Stegmaier, MD, Shiladitya Sengupta, PhD, BWH Dana-Farber Katherine Janeway, MD, Paul Shyn, MD, BWH Dana-Farber Guillermo Tearney, MD, MGH Matthew Steinhauser, MD, BWH Keith Joung, MD, PhD, MGH Ralph Weissleder, MD, PhD, Shannon Stott, PhD, MGH MGH Cigall Kadoch, PhD, Mario Suva, MD, PhD, MGH Dana-Farber Jonathan Whetstine, PhD, David Ting, MD, MGH MGH Featured Speakers Kenneth Anderson, MD Sheila Dharmarajan Jeffrey Golden, MD Director, Jerome Lipper Multiple Myeloma Head of Business Development, Chair of Pathology, Brigham and Women's Center, Kraft Family Professor of Medicine, Zelnick Media Capital Hospital, Ramzi S. Cotran Professor of Harvard Medical School Keith Dionne, PhD Pathology, Harvard Medical School Usman Azam, MD CEO, Constellation Pharmaceuticals Richard Gonzalez Global Head, Cell & Gene Therapies Don Dizon, MD CEO, AbbVie Unit, Novartis Clinical Co-Director, Gynecologic Marc Grodman, MD Monica Bertagnolli, MD Oncology, Massachusetts General CEO, BioReference Laboratories Chief, Division of Surgical Oncology, Hospital, Associate Professor of Daphne Haas-Kogan, MD Brigham and Women's Hospital, Medicine, Harvard Medical School Chair, Department of Radiation Oncology, Professor of Surgery, Glenn Dranoff, MD Dana-Farber Cancer Institute, Harvard Medical School Global Head of Exploratory Immuno- Professor of Radiation Oncology, James Bradner, MD Oncology, Novartis Institutes for Harvard Medical School President, Novartis Institutes Biomedical Research Daniel Haber, MD, PhD for BioMedical Research Jens Eckstein, PhD Director, Massachusetts General Robert Bradway President, SR One Hospital Cancer Center, Kurt J. CEO, Amgen Helmy Eltoukhy, PhD Isselbacher/Peter D. Schwartz Professor of Troy Brennan, MD CEO, Guardant Health Oncology, Harvard Medical School EVP and CMO, CVS Health Jeffrey Engelman, MD, PhD Nir Hacohen, PhD Joan Brugge, PhD Director, Thoracic Oncology and Director, Immunologist, Center for Immunology Professor, Director, Ludwig Center, Molecular Therapeutics, Medical and Inflammatory Diseases, Massachusetts Harvard Medical School Oncology, Massachusetts General Hospital, General Hospital Associate Professor, Medicine, Harvard Medical School Giovanni Caforio, MD Laurel Schwartz Associate Professor of CEO, Bristol-Myers Squibb Medicine, Harvard Medical School William Hait, MD, PhD Global Head, Janssen R&D, J&J Bruce Chabner, MD Maurice Ferre, MD Cancer Center Clinical Director CEO, Insightec Sean Harper, MD Emeritus, Massachusetts
Load more

Recommended publications
  • Guardant Health, Inc. Form 8-K Current Event Report Filed 2019-01
    SECURITIES AND EXCHANGE COMMISSION FORM 8-K Current report filing Filing Date: 2019-01-07 | Period of Report: 2019-01-07 SEC Accession No. 0001628280-19-000132 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 8-K | Act: 34 | File No.: 001-38683 | Film No.: 19512177 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2019 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 0001-576280 45-4139254 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation or organization) File Number) Identification No.) 505 Penobscot Dr. Redwood City, California 94063 (Address of principal executive offices) (Zip Code) 855-698-8887 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under
    [Show full text]
  • Boston University Journal of Science & Technology
    4 B.U. J. SCI. & TECH. L. 1 January 23, 1997 Boston University Journal of Science & Technology Law Symposium Financing the Biotech Industry: Can the Risks Be Reduced? Ronald Cass, Joshua Lerner, Farah H. Champsi, Stanley C. Erck, Jonathan R. Beckwith, Leslie E. Davis, Henri A. Termeer Table of Contents Speeches..........................................................................................................................[1] Dean Ronald Cass.............................................................................................[1] Joshua Lerner....................................................................................................[2] Farah Champsi..................................................................................................[8] Stanley Erck.....................................................................................................[18] Jonathan Beckwith.........................................................................................[24] Leslie Davis......................................................................................................[37] Henri Termeer.................................................................................................[47] Question and Answer Session..................................................................................[60] Financing the Biotech Industry: Can the Risks Be Reduced?† Jonathan R. Beckwith, Farah H. Champsi, Leslie E. Davis,* Stanley C. Erck, Joshua Lerner, Henri A. Termeer Dean Ronald Cass: 1. The biotechnology
    [Show full text]
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Guardant Health, Inc. Form 10-Q Quarterly Report Filed 2021-08-05
    SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Quarterly report pursuant to sections 13 or 15(d) Filing Date: 2021-08-05 | Period of Report: 2021-06-30 SEC Accession No. 0001576280-21-000080 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 10-Q | Act: 34 | File No.: 001-38683 | Film No.: 211148786 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ Delaware 45-4139254 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 505 Penobscot Dr. Redwood City, California, 94063 Registrant’s telephone number, including area code: (855) 698-8887 _______________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • AVEO PHARMACEUTICALS, INC. (Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 AVEO PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials: ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Proqr Therapeutics N.V
    ANNUAL REPORT 2017 Meaningful progress - Excited about the future PAGE I PAGE II ANNUAL MAGAZINE 2017 ANNUAL MAGAZINE 2017 our courage to do things differently University of Colorado and during his ACCOMPLISHMENTS – and challenge the status quo. career has earned a global reputation A QUICK GLANCE We can and will make a meaningful for translating cutting-edge science impact – changing the lives of into transformational new therapies Eluforsen (formely known as QR-010) for CF patients. Be it in a small way – for rare diseases including cystic fibro- • Completed second trial for eluforsen by improving one’s quality of life. sis, pulmonary fibrosis, pulmonary • Announced positive data from Or in a big way – by stopping artery hypertension, severe immuno- Phase 1b safety and tolerability study a disease or by curing patients. logic, and inflammatory diseases. • Received FDA Fast Track designation and Orphan Drug Designation (ODD) CREATING MEANINGFUL IMPACT At ProQR, we do it all in the interest Dave is excited to be part of ProQR’s in US and Europe of patients. We’re driven, deter- management team: “ProQR has • Granted two key patents mined, excited to make this differ- a patient-centric culture committed ence. Today, tomorrow and more to transforming lives. Applying our QR-110 for LCA 10 days to come, until we get it right. RNA editing platform to precision • IND clearance from FDA and IN THE INTEREST medicine in hereditary forms of commenced Phase 1/2 safety and Building ProQR blindness, dystrophic epidermolysis efficacy trial In 2017, we made important strides bullosa, cystic fibrosis and other • First patient in trial dosed in late 2017 in ProQR’s growth.
    [Show full text]
  • Orphan Drug Letters
    November 18, 2010 Kent Lieginger Senior Vice President, Managed Care and Customer Operations Genentech 1 DNA Way South San Franciso, CA 94080 Dear Dr. Lieginger: We are writing on behalf of a broad coalition of hospitals participating in the federal 340B drug discount program. We have been advised that Genentech has begun to withhold 340B pricing for orphan drugs purchased by a subset of our membership, primarily children’s and rural hospitals. We are aware that, under the Health Care and Education Reconciliation Act (HCERA), Congress established a statutory exclusion with respect to orphan drugs purchased by hospitals specifically added by the Patient Protection and Affordable Care Act (PPACA) to the 340B program under the Public Health Service Act, including freestanding cancer hospitals, children’s hospitals, sole community rural referral centers, and critical access hospitals. 1 However, we are deeply concerned with Genentech’s broad interpretation of the orphan drug exclusion, which Genentech has stated extends to all drugs that have been designated “orphan” by the FDA, regardless of the intended use of the drugs. We believe that, absent guidance from the Health Resources and Services Administration (HRSA) regarding the scope of the orphan drug exclusion, it is premature to withhold 340B pricing on orphan drugs. Accordingly, we request that Genentech resume its sale of orphan drugs to hospitals identified in PPACA at 340B prices until directed otherwise by HRSA. We understand that several manufacturers have decided to delay implementation until they receive further guidance from the government and ask that you follow their lead. Our concerns regarding your company’s interpretation are two-fold.
    [Show full text]
  • Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. As Recipient of BIO’S 2019 Henri A
    Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award May 29, 2019 NOVATO, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that the Biotechnology Innovation Organization (BIO) has awarded this year’s Henri A. Termeer Biotechnology Visionary Award to Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer, President and founder of Ultragenyx. The award, which will be presented to Dr. Kakkis on June 5 during the BIO 2019 International Convention keynote session, recognizes Dr. Kakkis’ transformative work to accelerate research and development of novel treatments for rare diseases. “Henri Termeer was a pioneer who worked relentlessly to do what many thought was impossible and bring therapies to patients with rare diseases,” said Dr. Kakkis. “I am deeply honored to receive this award from BIO.” “Dr. Kakkis’ innovative work has pushed the boundaries of our knowledge in rare diseases and through his efforts our industry better prioritizes treatments for rare and ultra-rare diseases and understands the unique needs of clinical trials in this category,” said Jim Greenwood, President and CEO of BIO. “His contributions to the study of rare diseases have been monumental for patients and families, and we’re looking forward to presenting him with this well-deserved honor at BIO 2019.” Over the last 25 years, Dr. Kakkis has spearheaded the development of many rare disease treatments, including an enzyme replacement therapy for the rare and debilitating disorder, mucopolysaccharidosis type I (MPS I), which was approved by the FDA in 2003.
    [Show full text]
  • Biotechnology Summit: Putting a Human Face on Biotechnology
    17Rla S. HRG. 106-677 BIOTECHNOLOGY SUMMIT: PUTTING A HUMAN FACE ON BIOTECHNOLOGY HEARING before the JOINT ECONOMIC COMMITTEE CONGRESS OF THE UNITED STATES ONE HUNDRED SIXTH CONGRESS FIRST SESSION September 29, 1999 PRINTED FOR THE USE OF THE JOINT ECONOMIC COMMITFEE U.S. GOVERNMENT PRINTING OFFICE WASHINGTON: 2000 CC 62-990 FOR SALE BY THE U.S. GOVERNMENT PRINTING OFFICE SUPERNTENDENTOF DOCUMEN CONGRESSIONALSALESOFFICEWASHINGTON, D.C20402 JOINT ECONOMIC COMMITTEE [Created pursuant to Sec. 5(a) of Public Law 304, 79th Congress] SENATE HOUSE OF REPRESENTATIVES CONNIE MACK, Florida, Chairman JIM SAXTON, New Jersey, Vice Chairman WILLIAM V. ROTH, JR., Delaware MARK SANFORD, South Carolina ROBERT F. BENNETT, Utah JOHN DOOLITTLE, California ROD GRAMS, Minnesota TOM CAMPBELL, California SAM BROWNBACK, Kansas JOSEPH R. PITTS, Pennsylvania JEFF SESSIONS, Alabama PAUL RYAN, Wisconsin CHARLES S. ROBB, Virginia PETE STARK, California PAUL S. SARBANES, Maryland CAROLYN B. MALONEY, New York EDWARD M. KENNEDY, Massachusetts DAVID MINGE, Minnesota JEFF BINGAMAN, New Mexico MELVIN L. WATT, North Carolina SHELLEY S. HYMES, Executive Director JAMES D. GWARTNEY, Chief Economist HOWARD ROSEN, Minority Staff Director (ii) CONTENTS OPENING STATEMENTS OF MEMBERS Senator Connie Mack, Chairman ........ ..................... I Representative Pete Stark, Ranking Minority Member ..... ...... 4 Senator Bill Frist . ......................................... 6 Senator Edward M. Kennedy ............................... 31 Senator Robert F. Bennett .. .............................. 33 Representative David Minge ................................ 36 Senator Jeff Sessions .............. ....................... 39 WITNESSES PANELI Statement of Carolyn Boyer-Fortier, Breast Cancer Survivor. ...... 8 Statement of Dr. Steven Shak, Staff Scientist and Senior Director of Medical Affairs, Genentech ........................... 11 Statement of Joan London, Rheumatoid Arthritis Patient .... ..... 13 Statement of Dr. Robert Bunning, Director of the Arthritis Program at National Rehabilitation Hospital.
    [Show full text]
  • How Scientist/Founders Lead Successful
    HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES Lynn Johnson Langer A DISSERTATION Submitted to the Ph.D. in Leadership & Change Program of Antioch University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May, 2008 This is to certify that the dissertation entitled: HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES prepared by Lynn Johnson Langer is approved in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Leadership & Change. Approved by: ______________________________________________________________________ Alan E. Guskin, Ph.D., Chair date ______________________________________________________________________ Jon Wergin, Ph.D., Committee Member date ______________________________________________________________________ Mitch Kusy, Ph.D., Committee Member date ______________________________________________________________________ Alice Sapienza, DBA, External Reader date Copyright 2008 Lynn Johnson Langer All rights reserved Acknowledgements I arrive at this place in my journey to becoming a scholar supported in love and friendship by so many people. I must thank first and foremost my husband, Eric Langer, who has supported me in many ways, but particularly with my education. I thank my daughter, Julia Annemarie, my study partner. We shout across the hall to each other, complaining and laughing about all the work. I thank her for her support and the opportunity to be a role model. She never once complained about the plays and events I missed because I was away at a residency. I thank my son, Adam and his wife, Megan who through their lives, remind me to follow my dreams. I thank my son, Benjamin, who shows me that through hard work, we can accomplish great things.
    [Show full text]
  • Monitoring Trace Levels of Ctdna Using Integration of Variant Reads
    Monitoring trace levels of ctDNA using 1 integration of variant reads 2 3 Jonathan C. M. Wan 4 Supervisor: Dr Nitzan Rosenfeld 5 6 Cancer Research UK Cambridge Institute 7 8 University of Cambridge This dissertation is submitted for the degree of 9 Doctor of Philosophy 10 Trinity College May 2019 11 Abstract 12 In patients with early-stage cancer, ctDNA detection rates can be low due to the presence of 13 few or no copies of any individual mutation in each sample. Sensitivity may be increased 14 by collecting larger plasma volumes, but this is not feasible in practice. Although cancers 15 typically have thousands of mutations in their genome, previous analyses measured only 16 individual or up to 32 tumour-specific mutations in plasma. 17 Here, we demonstrate that sensitivity can be greatly enhanced for any given input DNA 18 mass by analysing a large number of mutations via sequencing. We sequenced in plasma 2 4 19 10 -10 mutated loci per patient, using custom capture panels, whole exome (WES) or 20 whole genome sequencing (WGS). We developed a method for INtegration of VAriant Reads 21 (INVAR) that aggregates reads carrying tumour mutations across multiple mutant loci, and 22 assigns confidence to error-suppressed reads based on mutation context, fragment length and 23 tumour representation. This workflow combines a number of concepts in a novel approach in 24 order to quantify ctDNA with maximal sensitivity. 25 We applied INVARto plasma sequencing data from 45 patients with stage II-IV melanoma 26 and 26 healthy individuals. ctDNA was detected to 1 mutant molecule per million, and tu- 3 27 mour volumes of ~1cm .
    [Show full text]
  • Conference Day One Thursday, April 23Rd 2015 – Main Conference Room
    Conference Day One Thursday, April 23rd 2015 – Main Conference Room 8.55 Chairperson’s Opening Remarks Hans Schikan, Former Chief Executive Officer, Prosensa 9.00 Keynote: Data driving diagnostics - Clinically relevant information from ordinary photos, and an algorithm to aid in diagnoses of rare diseases Christoffer Nellaker, Research Fellow, Medical Research Foundation’s Functional Genomics Unit, Oxford University 9.30 Keynote: Is the market sustainable? Henri Termeer, Former Chairman, President and CEO, Genzyme (on video) 10.00 Speed Networking & Networking coffee break 11.00 Good medicine is good business: Transforming lives and meeting unmet needs Stephanie Okey, Senior Vice President and Head of North America, Genetic Diseases and US General Manager, Genzyme 11.20 The Great Debate: “The Price is Too Damn High!”…or is it? FOR: The orphan population is so small the rest of the population can more than cover the cost Ram Selvaraju, Managing Director, Equity Research – Healthcare, MLV & Co. AGAINST: First there was rare, now there’s ultra-rare. And it seems every other disease is rare and every other drug orphan. WE won’t be able to afford it – period. Ed Pazalla, VP, National Medical Director for Pharmacy Policy and Strategy, Aetna 12.00 Networking Lunch 1:00 Lunch session: Pediatric vouchers to expedite rare disease treatments in children Gayatri Rao, Director, Office of Orphan Product Development, FDA 1.30 2 x 40-minute roundtables with a 10 minute break in-between. Please sign up in the exhibition hall lounge. 1: How does miscommunication
    [Show full text]